The fifth CNS WHO classification mentions FGFR fusions as an essential or desirable feature in extraventricular neurocytoma (FGFR1-TACC1), dysembryoplastic neuroepithelial tumor (DNET, FGFR1 fusion or other FGFR1 alterations), polymorphous low-grade neuroepithelial tumor of the young (PLNTY, FGFR2-CTNNA3 and FGFR3 fusions) and multinodular and vacuolating neuronal tumor (MVNT, rarely FGFR2 fusions). This evidence concerns the gene FGFR2 and neuronal tumor.